In vivo experiments further validated that the combined treatment of cisplatin and DHODH inhibitor ta reduced tumor growth in NF2-deficient group, without inducing notable toxicity (Figs. 6H and  EV8G). This evidence concerns the gene NF2 and neoplasm.